peptide optimization FAQ

Increase to 150mcg for one week, then to 200mcg if improvement remains minimal. Most individuals over 40 require at least 150mcg to produce measurable changes in delta-wave sleep. 100mcg is often subtherapeutic in this age bracket. The lack of response at lower doses reflects cortisol resistance, not peptide quality or administration error. Titrate upward in 50mcg increments weekly until subjective sleep depth improves or until reaching 300mcg (the upper threshold before diminishing returns appear).

Cycle off DSIP for 5–7 days, then resume at the same dose. Unlike GABAergic sleep aids, DSIP does not produce tolerance through receptor downregulation. The mechanism is modulatory, not agonistic. Short-term loss of response usually reflects a temporary cortisol spike (stress, illness, travel) that overrides DSIP's effect rather than true pharmacological tolerance. A brief washout period resets the HPA axis without requiring dose escalation. If response remains blunted after resuming, evaluate cortisol levels via salivary testing at 10 PM and 6 AM. Persistently elevated evening cortisol may require additional interventions beyond DSIP monotherapy.

Reduce the dose by 25–50mcg or shift injection timing 15–20 minutes earlier. Morning grogginess after DSIP typically indicates the dose exceeded what the individual's HPA axis needed to restore delta sleep. The peptide pushed cortisol too low for too long, delaying the natural cortisol awakening response that occurs 30–60 minutes before waking. This is more common at doses above 250mcg in individuals who still have relatively intact circadian rhythm despite being in their 40s. Lower the dose before abandoning the protocol. Grogginess is a dosing issue, not a contraindication.

Reduce dosing to 12.5mg daily for two weeks, then re-escalate if tolerated. MK-677-induced water retention is mediated by aldosterone and cortisol modulation. It's typically transient and resolves within 3–4 weeks as the body adjusts to elevated IGF-1. Severe or persistent edema warrants cardiovascular evaluation, as it may indicate underlying heart failure exacerbated by fluid retention.

Monitor HbA1c monthly. MK-677 can cause mild insulin resistance in susceptible individuals, particularly those with baseline prediabetes (HbA1c 5.7–6.4%). If HbA1c rises above 6.0%, reduce MK-677 to 12.5mg or discontinue temporarily. The effect is dose-dependent and reversible. Stopping the compound normalizes glucose control within 2–3 weeks.

Continue through week 12 before evaluating biomarkers. Thymalin-driven immune changes require 8–12 weeks for measurable T-cell output increases. Subjective improvements lag objective data. MK-677 produces IGF-1 elevation within 4–6 weeks, but lean mass accretion and metabolic shifts follow at weeks 10–14. The timeline is biological, not pharmaceutical. Peptide-based protocols modulate gene expression and cellular function rather than forcing immediate receptor responses like conventional drugs.